menù
Phase: Phase I-II clinical trials
Principal Investigator: Dr. Pietrantonio Filippo
Main Facility: Gastrointestinal Oncology
Drug: MK-2870 (experimental drug) or MK-1022 (experimental drug)
Principal Investigator: Prof. Corradini Paolo
Main Facility: Haematology
Drug: GSK5926371, tricpsecific antibody anti CD19, CD20 CD3
Principal Investigator: Dott.ssa Verzoni Elena
Main Facility: Genitourinary Medical Oncology
Drug: MK-3120 + pembro
Phase: Phase I clinical trials
Principal Investigator: Dr. Di Nicola Massimo
Main Facility: Phase 1 Clinical Trials Unit (Early Clinical Drug Development Team – ECDD)
Drug: IMC-P115C, Bevacizumab, Olaparib, pembrolizumab/carboplatin/paclitaxel/pemetrexed, ipilimumab/nivolumab
Phase: Phase II clinical trials
Principal Investigator: Dr. Proto Claudia
Main Facility: Thoracic Oncology Unit
Drug: BMS-986504
Phase: Phase II-III clinical trials
Principal Investigator: Associate Professor Licitra Lisa Francesca Linda
Main Facility: Medical Oncology 3 – Head and Neck Cancers
Drug: AV-299
Drug: Ficerafusp alfa (BCA101)
Principal Investigator: Dott. Del Vecchio Michele
Main Facility: Medical Oncology: Melanomas
Drug: EIK1001
Drug: AZD4512 (CD22 β-glu exatecan)
Principal Investigator: Dott. Duca Matteo
Main Facility: Medical Oncology 1
Drug: BAY 3713372
Drug: ADT + placebo vs ADT + darolutamide (double blind)
Sign up for our newsletter to stay informed about news, events, and updates from the Institute
Subscribe